Patents by Inventor Gottfried Lichti
Gottfried Lichti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10179158Abstract: A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or IGT the drink comprising: at least one water soluble or water dispersible material selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8 g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml per serving, and fenugreek fibre in an amount in the range of from 1 g to 15 g.Type: GrantFiled: November 19, 2014Date of Patent: January 15, 2019Assignee: Omniblend Innovation PTY LTDInventors: Gottfried Lichti, Christopher Walter Lichti
-
Publication number: 20180139987Abstract: A powder composition for preparation of a drink for control of post prandial glycaemic profile, the powder composition comprising: ?alpha-glucosidase inhibitor selected from the group consisting of acarbose, miglitol, voglibose and mixtures thereof, in an amount in the range of from 0.01% to 15% w/w of the powder composition; ?viscosifying agent in an amount in the range of 5% to 30% w/w of the powder composition; protein in an amount in the range of 40% to 90% w/w of the pharmaceutical powder composition.Type: ApplicationFiled: April 22, 2016Publication date: May 24, 2018Applicant: OMNIBLEND INNOVATION PTY LTDInventors: Gottfried LICHTI, Christopher Walter LICHTI
-
Patent number: 9775801Abstract: A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising: at least one water soluble or water dispersible compound selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml (preferably in an amount of from 100 ml to 250 ml and more preferably from 125 ml to 175 ml) per serving, and wherein the drink exhibits shear banding when subject to the shear banding test herein described.Type: GrantFiled: March 20, 2017Date of Patent: October 3, 2017Assignee: Omniblend Innovation Pty Ltd.Inventors: Christopher Walter Lichti, Peter Richard Wynter Best, Janena Frances Best, Gottfried Lichti
-
Publication number: 20170189332Abstract: A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising: at least one water soluble or water dispersible compound selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml (preferably in an amount of from 100 ml to 250 ml and more preferably from 125 ml to 175 ml) per serving, and wherein the drink exhibits shear banding when subject to the shear banding test herein described.Type: ApplicationFiled: March 20, 2017Publication date: July 6, 2017Inventors: Christopher Walter LICHTI, Peter Richard Wynter BEST, Janena Frances BEST, Gottfried LICHTI
-
Patent number: 9675553Abstract: A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising: at least one water soluble or water dispersible compound selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8 g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml (preferably in an amount of from 100 ml to 250 ml and more preferably from 125 ml to 175 ml) per serving, and wherein the drink exhibits shear banding when subject to the shear banding test herein described.Type: GrantFiled: May 22, 2013Date of Patent: June 13, 2017Assignee: Omniblend Innovation Pty Ltd.Inventors: Christopher Walter Lichti, Peter Richard Wynter Best, Janena Frances Best, Gottfried Lichti
-
Publication number: 20160314475Abstract: A method and system is provided for verifying of the authenticity of a consumer product, the method including: providing an overt code on a consumer product, the overt code being readable prior to sale of the consumer product; providing a covert code on the consumer product, the covert code being revealed post sale of the consumer product; receiving a transmission of the covert code from a purchaser of the consumer product; verifying the covert code by reference to a database; if the covert code verifies the authenticity of the consumer product, transmitting an authentication signal to the purchaser; and cancelling the covert code and the overt code once the covert code has been used to verify the authenticity of the consumer product.Type: ApplicationFiled: December 16, 2014Publication date: October 27, 2016Inventors: Arie NUDEL, Gottfried LICHTI
-
Publication number: 20160287515Abstract: A method for treating type 2 diabetes in a human subject suffering from diabetes that comprises administering metformin in the period 100 to 5 minutes before a meal and subsequently consuming a protein food or protein derived drink before the meal.Type: ApplicationFiled: November 19, 2014Publication date: October 6, 2016Inventors: Gottfried LICHTI, Christopher Walter LICHTI
-
Patent number: 9402902Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: GrantFiled: December 23, 2013Date of Patent: August 2, 2016Assignee: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Publication number: 20150164793Abstract: A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising: at least one water soluble or water dispersible compound selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8 g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml (preferably in an amount of from 100 ml to 250 ml and more preferably from 125 ml to 175 ml) per serving, and wherein the drink exhibits shear banding when subject to the shear banding test herein described.Type: ApplicationFiled: May 22, 2013Publication date: June 18, 2015Inventors: Christopher Walter Lichti, Peter Richard Wynter Best, Janena Frances Best, Gottfried Lichti
-
Publication number: 20140112938Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Patent number: 8637025Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: GrantFiled: March 4, 2004Date of Patent: January 28, 2014Assignee: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Patent number: 8586705Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: GrantFiled: August 8, 2012Date of Patent: November 19, 2013Assignee: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Publication number: 20130022619Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission.Type: ApplicationFiled: April 11, 2011Publication date: January 24, 2013Inventors: Grant Thomas Rawlin, Damian Francis John Purcell, Robert John Center, Marit Kramski, Roy Michael Robins-Browne, Gottfried Lichti
-
Publication number: 20120302730Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: ApplicationFiled: August 8, 2012Publication date: November 29, 2012Applicant: STARPHARMA PTY LIMITEDInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Patent number: 8258259Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: GrantFiled: October 25, 2006Date of Patent: September 4, 2012Assignee: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Publication number: 20100196495Abstract: The invention relates to a method, composition and inhaler system for treatment or prophylaxis of influenza infection in one or more subjects by applying to a surface selected from air filters, sick room surfaces and respiratory mucosal membranes at least one immune material selected from antibodies and fragments thereof which bind a least one Influenza A antigen selected from the group consisting of H1, H3 and H5, the immune material being derived from hyperimmune milk products such as hyperimmune colostrum said hyperimmune milk products being prepared by inoculation of mammals with antigen composed of a least one Influenza A antigen selected from H1, H3 and H5.Type: ApplicationFiled: October 9, 2009Publication date: August 5, 2010Applicant: IMMURON LIMITEDInventors: Grant Thomas RAWLIN, Gottfried LICHTI, Roy Michael ROBINS-BROWNE
-
Publication number: 20090324723Abstract: A method for prophylaxis of infection of the respiratory tract of a subject by pathogenic airborne bacteria the method comprising administering to the subject by inhalation binding proteins directed against the bacteria. the pathogenic bacteria is a bacteria which survives inside phagocytes and the binding proteins are directed against said bacteria which survives inside phagocytes. The binding proteins comprise antibodies or antibody fragments directed against said bacteria which survives inside phagocytes. The binding proteins are selected from the group consisting of polyclonal antibodies, monoclonal antibodies, F(ab) fragments, F(ab?)2 fragments, antibody tip fragments, chimeric and humanized antibodies and fragments and recombinant antibodies and fragments.Type: ApplicationFiled: November 19, 2004Publication date: December 31, 2009Inventors: Grant Thomas Rawlin, Gottfried Lichti, Roy Michael Robins-Browne, Brian David Muller
-
Publication number: 20090169566Abstract: This invention relates to a bioactive composition comprising: (d) pH sensitive bioactive agent (e) an edible carboxylic acid containing moiety and (f) an edible alkalising moiety, wherein the proportion of said moieties and active agent provide pH control such that (i) when 400 mg of said composition is added to 20 ml of 0.033 normal hydrochloric acid and at a temperature of 37+/?3° C., the pH reaches a value in the range 4 to 8, and (ii) when 400 mg of said composition is added to 20 ml of deionised water at pH 7 and at a temperature of 37+/?3° C., the pH reaches a value less than 8.5.Type: ApplicationFiled: November 18, 2005Publication date: July 2, 2009Applicant: Anadis Ltd.Inventors: Grant Thomas Rawlin, Gottfried Lichti, Roy Michael Robins-Browne
-
Publication number: 20090118467Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: ApplicationFiled: October 25, 2006Publication date: May 7, 2009Applicant: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Publication number: 20070053917Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: ApplicationFiled: March 4, 2004Publication date: March 8, 2007Inventors: Roy Robins-Browne, Grant Rawlin, Gottfried Lichti